AbbVie’s Rinvoq gains EU approval for juvenile arthritis
Investing.com
AbbVie Inc. announced that the European Commission has approved its drug Rinvoq (upadacitinib) for the treatment of active polyarticular juvenile idiopathic arthritis. This approval applies to patients aged two years and older who have not adequately responded to previous disease-modifying anti-rheumatic drugs. Rinvoq is already approved in the EU for several other conditions, including rheumatoid arthritis and psoriatic arthritis.
Read the full story
This is a short summary. The complete article is published by Investing.com.
Headline and summary aggregated from public news feeds. For information only — not financial advice.